Breaking News

Dream of in vivo CAR-T therapy advances with new study

March 20, 2026
avatar-angus-chen
Cancer Reporter

Although most readers of this newsletter probably know what the thymus is, I'd wager that a lot of adults aren't familiar. That's probably because the thymus, a small organ that can fit in the palm of your hand, really is only known to have an important role during childhood — when it acts a kind of training ground for T cells. After puberty, it starts shrinking, but a couple of new studies out in Nature this week suggest that the thymus might be more important for adult health than previously thought.

In the pair of papers, researchers provided some evidence suggesting that better thymic health is associated with healthier aging and better responses to immunotherapy. In one study, authors used a deep-learning model to analyze CT chest images from 5,000 participants and create a "thymic health score," which was related to the size of the thymus, finding that higher or better scores correlated with lower incidence and mortality of certain diseases like lung cancer or cardiovascular disease. In the other paper, the same researchers found higher thymic health scores also correlated with better outcomes in patients receiving immune checkpoint therapy.

Interesting! This adds to some evidence that the thymus might be doing something to maintain immune health as we age (a Massachusetts General Hospital observational study in 2023 had a similar conclusion), an observation that would upend current anatomical dogma. For me, the studies raise some intriguing new questions: What is the role of thymus in adult health, if there truly is one, and how could that biology be leveraged to improve or predict immunotherapy outcomes in cancer?


Adobe

STAT+ | Clearing tumors in mice, Azalea Therapeutics advances dream of in vivo CAR-T therapy

A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut costs and expand access.

By Angus Chen


STAT+ | Novartis picks up experimental breast cancer therapy for $2B

Novartis has been on the hunt for its next blockbusters as some of its reliable best sellers have started to face generic competition.

By Andrew Joseph


STAT+ | Six drugmakers, six months: Charting the FDA's course in the post-Prasad era

In this week's "Adam's Biotech Scorecard," Adam points out what to look for to get a better sense of the FDA's positions of regulatory flexibility.

By Adam Feuerstein



Minoli Perera, associate professor of pharmacology at Northwestern University, in her lab.
Kayana Szymczak for STAT

Researchers surveyed by STAT detail the toll of grant cuts: labs shutting down, data unanalyzed

Interviews reveal stalled experiments and uncertain futures as NIH-funded researchers navigate disruptions highlighted in a STAT survey.

By Jonathan Wosen and Anil Oza


Smoking rates are at a historic low. You're not hearing about it from the government

CDC data shows 9.9% of U.S. adults reported smoking cigarettes in 2024. Because of budget cuts, government gathered the data, left it to others to analyze.

By Sarah Todd


STAT+ | NIH will spend its full budget this year, agency director promises House appropriators

NIH Director Jay Bhattacharya promises Congress his agency will spend its full $48.7 billion budget after a slow start in approving grants.

By Jonathan Wosen


More around STAT

In case you missed it

  • How Susie Wiles is balancing one of the most powerful jobs in the world with her cancer diagnosis, CNN
  • Why is colorectal cancer affecting generations differently?, NPR

Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments